TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34251536
Drug: TTO NE
Normalized name: Ne
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTO NE + ADA Gel
Study: 34251536
Drug: ADA Marketed
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA Marketed Gel
Study: 34543460
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in pristine bone (CT)
Study: 35259925
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system blockers
Study: 35051663
Drug: aPDT (antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: aPDT (antimicrobial photodynamic therapy) using a curcumin-based photosensitizer, exposed to 660 nm light for 5 minutes at 200 J/cm2 fluency.
Study: 35333743
Drug: Trazodone (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (9 to 12 mg/kg)
Study: 34534319
Drug: Preseason HAI
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseason HAI antibody titers
Study: 35871010
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (ICBT) with pre-treatment assessment interview
Study: 32472526
Drug: Antiplatelet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet and anticoagulant therapies
Study: 35643967
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate 0.5%
Study: 35678032
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 300 mg with fexofenadine 60 mg and pseudoephedrine 120 mg
Study: 35678032
Drug: Water (control)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (control) with fexofenadine 60 mg and pseudoephedrine 120 mg
Study: 32901235
Drug: Paracetamol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (15 mg/kg)
Study: 33220090
Drug: Transcrestal sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcrestal sinus floor elevation (TSFE) with bovine‐derived xenograft and implant placement
Study: 33220090
Drug: Lateral sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral sinus floor elevation (LSFE) with bovine‐derived xenograft and implant placement
Study: 36495879
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan 5.4 mg/kg
Study: 36471429
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral administration of cephalexin and metronidazole
Study: 32274746
Drug: Scoring balloon
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scoring balloon angioplasty (SBA) prior to drug-coated balloon angioplasty (DCB)
Study: 33207242
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) combined with the same language treatment
Study: 32215674
Drug: r-ESWT (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-ESWT (2000 pulses of shockwave at 2.0 to 3.0 bar weekly for three weeks)
Study: 32470486
Drug: Ruxolitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib plus standard-of-care treatment
Study: 32470486
Drug: Placebo based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo based on standard-of-care treatment
Study: 37316311
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches
Study: 36190739
Drug: All agents
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All agents
Study: 36400597
Drug: Flutamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (125 mg orally daily)
Study: 34313697
Drug: Systemic hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Systemic hydrocortisone treatment initiated 7 to 14 days after birth
Study: 32217498
Drug: Tablet-based TSN
Normalized name: TSN-084
DrugBank: TSN-084 (DB18306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based TSN app prototype
Study: 33144157
Drug: Higher adiponectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher adiponectin levels (per 5-µg/ml increase)
Study: 35807858
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of carbonated water plus two kiwifruit (intervention)
Study: 35807858
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of carbonated water (control)
Study: 32538550
Drug: Standard‐of‐care basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐of‐care basal insulin analogues (SOC‐BI)
Study: 35504634
Drug: Temporary interruption
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary interruption of low-dose methotrexate treatment
Study: 35504634
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (continuing low-dose methotrexate treatment)
Study: 33065060
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg)
Study: 91276441
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg twice a day for three weeks)
Study: 36401662
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (70 mL, 6.4 mmol NO3−)
Study: 33377959
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy
Study: 34898074
Drug: Luobufukebiri Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luobufukebiri Pills (LP), 10 pills bid for 12 weeks
Study: 34898074
Drug: Luobufukebiri Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luobufukebiri Pills (LP) vs Vitamin E soft capsules
Study: 35717146
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (90-minute weekly sessions for 6 weeks plus two booster sessions)
Study: 33051264
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone
Study: 36055329
Drug: Short treatment
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short treatment with a carbapenem
Study: 36055329
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment with a carbapenem
Study: 33575989
Drug: Intravenous Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Methylprednisolone (IVMP) 30 mg/kg/d for 3 days followed by oral prednisolone taper
Study: 35175308
Drug: Intravenous Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Methylprednisolone (IVMP)
Study: 33575989
Drug: Oral Prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Prednisolone (OP) 4 mg/kg/d for two weeks followed by taper
Study: 33575989
Drug: Oral Prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Prednisolone (OP)
Study: 36029412
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg (ipi3)
Study: 36029412
Drug: high-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose interferon (HDI)
Study: 33512814
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block with 20 mL 0.5% bupivacaine
Study: 33512814
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia using Ranawat cocktail (60 mL applied to subacromial space and glenohumeral joint)
Study: 33909203
Drug: Lapatinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib + capecitabine (L + C)
Study: 33051083
Drug: Lowest postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowest postoperative haemoglobin concentration <110 g L−1
Study: 33051083
Drug: Postoperative haemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative haemoglobin concentrations <88 g L−1
Study: 33051083
Drug: Postoperative haemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative haemoglobin concentrations >113 g L−1
Study: 33051083
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with lowest postoperative haemoglobin concentration >110 g L−1
Study: 34368943
Drug: Sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual (SL) 50 mg ketamine lozenge
Study: 34368943
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) 50 mg ketamine lozenge
Study: 34368943
Drug: SL placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL placebo lozenge
Study: 34368943
Drug: PO placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO placebo lozenge
Study: 35993480
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg)
Study: 33470329
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAPT) - aspirin, ticagrelor, and tirofiban
Study: 32896775
Drug: Lurasidone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 160 mg/day
Study: 34129720
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of dopamine during donor management
Study: 34129720
Drug: Tidal volumes
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volumes ≤8 ml/kg predicted body weight
Study: 32544575
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (HFRT)
Study: 32113878
Drug: Dinoprostone 3
Normalized name: dinoprostone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone 3 mg vaginally
Study: 34786651
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 or 20 mg once daily, titrated based on serum potassium and estimated glomerular filtration rate.
Study: 34786651
Drug: Finerenone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (10 to 20 mg)
Study: 33239108
Drug: 10 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/kg/min landiolol infusion
Study: 33239108
Drug: Termination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Termination of landiolol infusion
Study: 33239108
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of landiolol
Study: 32703038
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg policosanol + 20 mg atorvastatin (group D)
Study: 35643280
Drug: OIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OIT with placebo antihistamines
Study: 35643280
Drug: OIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OIT with antihistamines
Study: 35329390
Drug: Physiotherapy program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy program to train strength and coordination of the masticatory muscles, details on dosage and duration not available.
Study: 37804430
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg
Study: 36119062
Drug: BK-SE36 (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK-SE36 (intramuscular route)
Study: 36119062
Drug: BK-SE36 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK-SE36 (subcutaneous route)
Study: 36119062
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Synflorix® via IM route)
Study: 35434945
Drug: Okra whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okra whole fruit capsules (1,000 mg) taken orally every 6 hours for 8 weeks
Study: 35434945
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken orally every 6 hours for 8 weeks
Study: 32252101
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg BM)
Study: 36581796
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg)
Study: 32362221
Drug: Modified quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified quadruple therapy (rabeprazole 20 mg bid, amoxicillin 1 g bid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid)
Study: 32362221
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (rabeprazole 20 mg bid, bismuth subcitrate 300 mg qid, metronidazole 500 mg tid, tetracycline 500 mg qid)
Study: 32433709
Drug: Blood cadmium
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood cadmium quartile 4 (1.63-57.81 μg/L)
Study: 32433709
Drug: Lowest blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest blood cadmium quartile (0.00-0.53 μg/L)
Study: 32019509
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (GCBT) plus treatment as usual (TAU)
Study: 32019509
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list (WL) plus treatment as usual (TAU)
Study: 35505452
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia pretreatment with lidocaine‐prilocaine cream (EMLA)
Study: 35505452
Drug: Water‐based cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water‐based cream (placebo)
Study: 34647992
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg once daily for 12 weeks
Study: 32377822
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment for non-infectious uveitis
Study: 33341062
Drug: Usual preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual preparation in auscultation learning strategies
Study: 32171774
Drug: Levothyroxine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (starting dose of 50 µg daily)
Study: 36494824
Drug: Usual practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual practice (control group) with additional monthly data contribution.
Study: 32431191
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment once a day (QD)
Study: 37929602
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg daily
Study: 38587822
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single dose)
Study: 35514022
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (maximum dose 40 mg/daily)
Study: 33478397
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D2 supplementation (60,000 IU/week for 12 weeks)
Study: 33478397
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D2 supplementation (20,000 IU/week for 12 weeks)
Study: 33478397
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D2 supplementation
Study: 33478397
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D2 supplementation
Study: 32679209
Drug: Booster injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster injection
Study: 32417993
Drug: Sorafenib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib dose interruption
Study: 32417993
Drug: Sorafenib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib dose reduction
Study: 33742551
Drug: 0.20 mg
Normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg ranibizumab
Study: 33742551
Drug: 0.12 mg
Normalized name: iodine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg ranibizumab
Study: 34467531
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional treatment)
Study: 33675460
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (4-mg)
Study: 33675460
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2-mg)
Study: 35345256
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine hydration therapy)
Study: 36190737
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral and intravenous)
Study: 35109140
Drug: High-dose TG-DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TG-DHA supplementation (2,040 mg DHA daily for six months)
Study: 35991062
Drug: Daily life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily life activities without any intervention (Control)
Study: 37001911
Drug: Mirikizumab 600
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 600 mg
Study: 35171954
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing a mixture of Boswellia serrata Roxb., chlorophyll, green tea extract, glucosamine, chondroitin sulfate, hyaluronic acid, and non-hydrolised type II collagen for 60 days
Study: 35606829
Drug: Empiric antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotics (ampicillin and gentamicin)
Study: 35994847
Drug: Diterpene ginkgolides
Normalized name: terpene resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diterpene ginkgolides meglumine injection (DGMI)
Study: 35217440
Drug: Tanezumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 2.5 mg, subcutaneous every 8 weeks for 56 weeks
Study: 38650049
Drug: Tanezumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 2.5 mg
Study: 32304415
Drug: 1‐deamino‐8‐D‐arginine vasopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐deamino‐8‐D‐arginine vasopressin (0.4 µg/kg) + platelet transfusion (2 U)
Study: 32453198
Drug: Metronidazole as
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole as part of multimodal therapy
Study: 32722939
Drug: O3FAs/PPs group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: O3FAs/PPs group: Oral omega-3 fatty acids (O3FAs) two capsules twice daily (total daily dose of 1040 mg/day) for 6 months with punctal plugs.
Study: 32722939
Drug: PPs group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPs group: Punctal plugs with oral placebo.
Study: 35218145
Drug: Family-based behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioural social facilitation treatment (FBSFT)
Study: 32106777
Drug: Revefenacin 175
Normalized name: REVEFENACIN 175MCG/3ML INHL SOLN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 175 µg
Study: 36108881
Drug: Single-row repair
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-row repair with horizontal LHBT augmentation
Study: 35466521
Drug: b.i.d. amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. amoxicillin for 7 days
Study: 35466521
Drug: b.i.d. amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. amoxicillin for 10 days
Study: 35466521
Drug: t.i.d. amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. amoxicillin for 7 days
Study: 35466521
Drug: t.i.d. amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. amoxicillin for 10 days
Study: 35081747
Drug: Atezolizumab +
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab + Bevacizumab prior to or in combination with TACE
Study: 33798298
Drug: Jin's three-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin's three-needle therapy and motor relearning regimen
Study: 32735782
Drug: Cannabidiol 400
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 400 mg
Study: 39069154
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control)
Study: 32737054
Drug: dDAVP oral
Normalized name: DDAVP Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: dDAVP oral lyophilisate administered sublingually as a single dose after a water load.
Study: 32737054
Drug: dDAVP oral
Normalized name: DDAVP Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: dDAVP oral lyophilisate
Study: 33947446
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) approximately 500 mL
Study: 33369704
Drug: Rucaparib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 500 mg twice daily
Study: 38971950
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg twice daily
Study: 32925337
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg)